These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2504810)

  • 21. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
    Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
    Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The contribution of experimental models to the physiopathology and treatment of infectious endocarditis].
    Fantin B
    Rev Prat; 1998 Mar; 48(5):492-6. PubMed ID: 9781110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
    Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
    Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
    J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
    Moody JA; Gerding DN; Peterson LR
    Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
    Chambers HF
    Infect Dis Clin North Am; 1993 Mar; 7(1):69-80. PubMed ID: 8463654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?
    MacGowan A; Rogers C; Bowker K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S214-20. PubMed ID: 11524721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental models of CNS infections. Contributions to concepts of disease and treatment.
    Täuber MG; Brooks-Fournier RA; Sande MA
    Neurol Clin; 1986 Feb; 4(1):249-64. PubMed ID: 3523203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic antagonism and synergy.
    Lancet; 1978 Jul; 2(8080):80-2. PubMed ID: 78302
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of antimicrobials on blood cultures in endocarditis.
    McKenzie R; Reimer LG
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):165-72. PubMed ID: 3126019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental endocarditis: a review of its relevance to human endocarditis.
    Carbon C
    J Antimicrob Chemother; 1993 May; 31 Suppl D():71-85. PubMed ID: 8335526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Quinolones in the treatment of bacterial endocarditis].
    Krcméry V; Goljer J
    Cas Lek Cesk; 1990 Aug; 129(33):1043-4. PubMed ID: 2208248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental infective endocarditis.
    Freedman LR; Valone J
    Prog Cardiovasc Dis; 1979; 22(3):169-80. PubMed ID: 388518
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of bacterial endocarditis].
    Jeljaszewicz J; Hryniewicz W
    Kardiol Pol; 1978; 21(5):467-73. PubMed ID: 713237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.